DUBLIN–(BUSINESS WIRE)–The “Histone Deacetylase 6 – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 20+ companies and 26+ pipeline drugs in Histone Deacetylase 6 (HDAC 6) inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Histone Deacetylase 6 (HDAC 6) inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Histone Deacetylase 6 (HDAC 6) inhibitors.
Histone Deacetylase 6 (HDAC 6) inhibitors Emerging Drugs Chapters
This segment of the Histone Deacetylase 6 (HDAC 6) inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
The publisher’s report covers around 26+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Histone Deacetylase 6 (HDAC 6) inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Histone Deacetylase 6 (HDAC 6) inhibitors therapeutic drugs key players involved in developing key drugs.
Histone Deacetylase 6 (HDAC 6) inhibitors Report Insights
- Histone Deacetylase 6 (HDAC 6) inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Histone Deacetylase 6 (HDAC 6) inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
- How many companies are developing Histone Deacetylase 6 (HDAC 6) inhibitors drugs?
- How many Histone Deacetylase 6 (HDAC 6) inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Histone Deacetylase 6 (HDAC 6) inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Histone Deacetylase 6 (HDAC 6) inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Histone Deacetylase 6 (HDAC 6) inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Companies Mentioned
- Celgene Corporation
- Karus Therapeutics
- Regenacy Pharmaceuticals
- Chong Kun Dang
- Shuttle Pharmaceuticals
- Tenaya Therapeutics
- Hillstream BioPharma
- Viracta Therapeutics
- CStone Pharmaceuticals
- Kancera
- OnKure Therapeutics
- Eikonizo Therapeutics
- Quimatryx
- AnnJi Pharmaceutical
- Jubilant Therapeutics
- Oryzon
- Augustine Therapeutics
- Advaite
- 4SC
- Merck Sharp & Dohme
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sy9pr3
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900